Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 12/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26816640 | 0.86 | BRD4 (0.48) | BRD4BRD2GRM5CRBNCYP11B1 | |
| SCHEMBL26816950 | 0.83 | BRD4 (0.45) | BRD4BRD2GRM5CRBNCYP11B1 | |
| SCHEMBL20850802 | 0.79 | BRD4 (0.50) | BRD4BRD2GRM5CRBNALDH1A1 | |
| SCHEMBL16189946 | 0.76 | BRD4 (0.41) | BRD4BRD2CRBNCYP11B1CYP11B2 | |
| SCHEMBL6195706 | 0.75 | — | — | |
| SCHEMBL23542652 | 0.74 | PKM (0.36) | GRM5PKMALDH1A1 | |
| SCHEMBL25672130 | 0.74 | CRBN (0.37) | BRD4BRD2CRBNCYP11B1CYP11B2 | |
| SCHEMBL21557329 | 0.73 | CHRM2 (0.42) | BRD4BRD2CRBNCYP11B1CYP11B2 | |
| SCHEMBL8295687 | 0.73 | CHRM2 (0.35) | GRM5PKMCHRM2CHRM3ALDH1A1 | |
| SCHEMBL7606492 | 0.71 | CHRM2 (0.37) | GRM5CYP11B1CYP11B2PKMCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081328-A1 | HISTONE DEACETYLASE 6 INHIBITOR COMPOUNDS AND USES THEREOF | VALO HEALTH, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| US-7592419-B2 | Macrocyclic inhibitors of hepatitis C virus NS3-serine protease | SCHERING CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | BRD4 1871/4885BRD2 3445/4885GRM5 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.